ROIVW (Roivant Sciences) Float Percentage Of Total Shares Outstanding: N/A (As of Jun. 28, 2026)


ROIVW Roivant Sciences Ltd ROIVW
55 GF Score
Price $2.75
! 7 Warning Signs
View Full Analysis

What is Roivant Sciences Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Roivant Sciences's float shares is 0.00 Mil. Roivant Sciences's total shares outstanding is 0.00 Mil. Roivant Sciences's float percentage of total shares outstanding is N/A.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Roivant Sciences's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Roivant Sciences's Institutional Ownership is 0.00%.

ROIVW
55GF Score
Roivant Sciences Ltd ROIVW
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roivant Sciences Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Roivant Sciences's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roivant Sciences Business Description

Other Exchanges ROIV:USA87S:Germany
Address 50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
55GF Score

Get the complete analysis for ROIVW

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.75
Price